Structure Therapeutics (GPCR) Enterprise Value (2022 - 2026)

Structure Therapeutics' Enterprise Value history runs 5 years deep, the most recent figure standing at -$2.6 billion for Q1 2026.

• On a quarterly basis, Enterprise Value fell 70.55% year-over-year to -$2.6 billion in Q1 2026; TTM through Mar 2026 was -$2.6 billion, a 70.55% decrease from a year earlier, with the FY2025 full-year figure at -$1.4 billion, up 9.01% from the prior year.
• Enterprise Value fell to -$2.6 billion in Q1 2026 per GPCR's latest filing, from -$1.4 billion in the prior quarter.
• Across five years, Enterprise Value topped out at -$90.8 million in Q4 2022 and bottomed at -$2.6 billion in Q1 2026.
• The 5-year median for Enterprise Value is -$850.9 million (2024), against an average of -$948.3 million.
• Across the five-year window, Enterprise Value tumbled 414.44% in 2023 and advanced 15.17% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$90.8 million in 2022, then tumbled by 414.44% to -$467.3 million in 2023, then sank by 240.1% to -$1.6 billion in 2024, then rose by 9.01% to -$1.4 billion in 2025, then slumped by 79.45% to -$2.6 billion in 2026.
• Per Business Quant, the three latest GPCR Enterprise Value figures stand at -$2.6 billion (Q1 2026), -$1.4 billion (Q4 2025), and -$1.5 billion (Q3 2025).